Table 5.
Characteristic | With Dementia | Without Dementia | P a | ||
---|---|---|---|---|---|
Mean | 95% CI | Mean | 95% CI | ||
Age, y | 77.5 | 75.8–79.1 | 66.8 | 65.4–68.3 | 0.000 |
Education, y | 7.0 | 6.0–7.9 | 10.0 | 9.2–10.7 | 0.000 |
Disease duration, y | 10.4 | 8.3–12.4 | 6.9 | 6.2–7.5 | 0.007 |
Levodopa | |||||
Time on treatment, y | 7.3 | 5.7–8.9 | 5.7 | 5.0–6.3 | 0.244 |
Dose, mg/d | 828.7 | 727.5–929.9 | 681.3 | 639.5–723.0 | 0.003 |
SPES‐Scopa | |||||
Section 1 | 20.9 | 19.3–22.6 | 17.1 | 16.4–17.9 | 0.000 |
Section 2 | 11.7 | 10.5–12.9 | 8.4 | 8.0–8.9 | 0.000 |
Section 3 | 3.7 | 2.8–4.6 | 3.6 | 3.1–4.0 | 0.980 |
Total | 36.4 | 33.0–39.8 | 29.1 | 27.6–30.5 | 0.000 |
Schwab & England | 58.9 | 53.4–64.3 | 72.7 | 71.0–74.4 | 0.000 |
MMSE | 17.6 | 16.0–19.2 | 25.3 | 24.9–25.7 | 0.000 |
HADS | |||||
Anxiety | 8.9 | 7.9–9.9 | 6.9 | 6.4–7.4 | 0.001 |
Depression | 8.9 | 7.8–9.9 | 6.2 | 5.7–6.7 | 0.000 |
PIMS | 24.8 | 22.3–27.3 | 18.2 | 16.9–19.6 | 0.000 |
SCOPA‐Psychosocial | 13.3 | 11.4–15.2 | 9.3 | 8.5–10.1 | 0.000 |
PPRS | 2.6 | 2.1–3.1 | 1.2 | 1.0–1.4 | 0.000 |
CISI‐PD | 15.0 | 13.6–16.4 | 10.2 | 9.7–10.8 | 0.000 |
PD‐CRS | |||||
Subcortical | 22.7 | 18.3–27.2 | 56.2 | 52.4–59.9 | 0.000 |
Cortical | 19.9 | 17.2–22.5 | 25.0 | 24.1–29.9 | 0.000 |
Total | 41.7 | 28.5–48.2 | 87.4 | 83.0–91.8 | 0.000 |
P values were determined using a Mann‐Whitney U test or a t test; in either case, P values ≤ 0.05 were considered significant.
CI, confidence interval; SPES‐Scopa, Short Parkinson's Evaluation Scale‐Scales for Outcomes in Parkinson's Disease; MMSE, Mini‐Mental Status Examination; HADS, Hospital Anxiety and Depression Scale; PIMS, Parkinson's Impact Scale; SCOPA, Scales for Outcomes in Parkinson's Disease; PPRS, Parkinson's Psychosis Rating Scale; CISI‐PD, Clinical Impression of Severity Index for Parkinson's Disease; PD‐CRS, Parkinson's Disease Cognitive Rating Scale.